Clinical Trial Update: Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial update reports safety and preliminary efficacy of a metabolically armed CAR-T cell therapy targeting EGFRvIII in recurrent glioblastoma, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• EGFRvIII-targeted metabolically armed CAR-T cell therapy

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Glioblastoma (GBM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING